(RTTNews) - Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced on Friday that the U.S. Food and Drug Administration will not meet the November 22, 2026, Prescription Drug User Fee Act target action date for its Biologics
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.
